Purple Biotech Ltd.
PPBTNASDAQHealthcare● Active
$2.92
$-0.05(-1.68%)
Market Cap$403205
P/E Ratio—
52W High$29
52W Low$2.52
Purple Biotech Ltd. (PPBT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PPBT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.09
Est. -$3.80 · +97.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
PPBT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.98 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$3.80 | -$0.09 | +97.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 13, 2026 | -$3.40 | -$19.85 | -483.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.26 | -$0.29 | -11.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.21 | -$0.40 | -90.5% | — | — | — |
| — Q2 FY2025 | May 21, 2025 | — | -$0.17 | — | — | — | — |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$0.22 | -$0.26 | -18.2% | — | — | — |
| ▼ Q4 FY2024 | Nov 15, 2024 | -$1.20 | -$1.37 | -14.2% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.98
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.09
EPS Est.
-$3.80
EPS Surpr.
+97.6%
Revenue
—
Q1 FY2026
Mar 13, 2026Miss
EPS Actual
-$19.85
EPS Est.
-$3.40
EPS Surpr.
-483.8%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.29
EPS Est.
-$0.26
EPS Surpr.
-11.5%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.21
EPS Surpr.
-90.5%
Revenue
—
Q2 FY2025
May 21, 2025
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.22
EPS Surpr.
-18.2%
Revenue
—
Q4 FY2024
Nov 15, 2024Miss
EPS Actual
-$1.37
EPS Est.
-$1.20
EPS Surpr.
-14.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-2.51 | $-2.51 | $-2.51 | 1 |
| Q3 FY2026 | $-1.73 | $-1.73 | $-1.73 | 1 |
| Q2 FY2026 | $-0.98 | $-0.98 | $-0.98 | 1 |
| Q1 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2025 | $-3.40 | $-3.40 | $-3.40 | 1 |
| Q3 FY2025 | $-2.60 | $-2.60 | $-2.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +97.6% | $3.69 | $3.94 | +6.78% |
| ▼ Q1 FY2026 | Mar 13, 2026 | -483.8% | $3.84 | $4.10 | +6.77% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -11.5% | $7.40 | $7.18 | -2.97% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -90.5% | $22.60 | $21.50 | -4.87% |
| — Q2 FY2025 | May 21, 2025 | — | $24.10 | $23.70 | -1.66% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -18.2% | $28.10 | $27.15 | -3.38% |
| ▼ Q4 FY2024 | Nov 15, 2024 | -14.2% | $25.20 | $25.05 | -0.60% |
| ▼ Q3 FY2024 | Aug 16, 2024 | -900.0% | $72.38 | $73.44 | +1.46% |
Q2 FY2026+6.78%
Report Date
May 15, 2026
EPS Beat/Miss
+97.6%
Price Before
$3.69
Price After
$3.94
Q1 FY2026+6.77%
Report Date
Mar 13, 2026
EPS Beat/Miss
-483.8%
Price Before
$3.84
Price After
$4.10
Q4 FY2025-2.97%
Report Date
Nov 14, 2025
EPS Beat/Miss
-11.5%
Price Before
$7.40
Price After
$7.18
Q3 FY2025-4.87%
Report Date
Aug 6, 2025
EPS Beat/Miss
-90.5%
Price Before
$22.60
Price After
$21.50
Q2 FY2025-1.66%
Report Date
May 21, 2025
EPS Beat/Miss
—
Price Before
$24.10
Price After
$23.70
Q1 FY2025-3.38%
Report Date
Mar 10, 2025
EPS Beat/Miss
-18.2%
Price Before
$28.10
Price After
$27.15
Q4 FY2024-0.60%
Report Date
Nov 15, 2024
EPS Beat/Miss
-14.2%
Price Before
$25.20
Price After
$25.05
Q3 FY2024+1.46%
Report Date
Aug 16, 2024
EPS Beat/Miss
-900.0%
Price Before
$72.38
Price After
$73.44
Avg Beat Reaction+6.78%
Avg Miss Reaction-0.60%
Beat Rate1 / 8 quarters
Largest Move+6.78% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PPBT ends December
Purple Biotech Ltd. (PPBT) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.09 — beating the analyst consensus of $-3.80 by +97.6%. The next PPBT earnings date is expected around September 1, 2026.
Each quarter, investors track PPBT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PPBT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PPBT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PPBT earnings · 5 questionsPurple Biotech Ltd.'s next earnings report is expected around September 1, 2026. PPBT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PPBT historically reports after market close (AMC).
PPBT earnings datewhen is PPBT earningsPPBT next earnings datewhen does PPBT report earningsPPBT earnings calendar
▸ Source: FMP · Purple Biotech Ltd. SEC filings · US GAAP · Purple Biotech Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026